Navigation Links
Low socioeconomic status increases depression risk in rheumatoid arthritis patients
Date:1/26/2011

A recent study confirmed that low socioeconomic status (SES) is associated with higher risk of depressive symptoms in patients with rheumatoid arthritis (RA). Statistically significant differences in race, public versus tertiary-care hospital, disability and medications were found between depressed and non-depressed patients. Study findings are reported in the February issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

Roughly 1.3 million Americans are affected by RAa chronic autoimmune disease that can cause functional limitations and may lead to physical disability in many patients. Prior studies have shown that depression is common, occurring in 13% to 42% of RA patients and is associated with worse outcomes, including greater risk of heart attack, suicide, and death. In the U.S., socioeconomic position as measured by race, gender, age, income, education and health access has significant impact on overall health.

Mary Margaretten, M.D., from the Arthritis Research Group at the University of California, San Francisco (UCSF) and lead study author explained, "We assessed the extent to which low SES influences the relationship between disability and depression in order to better identify those patients at higher risk for depression." Researchers used data obtained from the UCSF RA cohort in which participants were enrolled from an urban county, public hospital that serves the poor and a referral, tertiary-care medical center. The data included 824 visits for 466 patients, 223 from the public hospital and 243 from the tertiary-care clinic.

Analysis showed that 37% of participants had moderate to severe depression, scoring 10 or higher on the Patient Health Questionnaire (PHQ-9). The mean Health Assessment Questionnaire (HAQ) score was 1.2 and the disease activity score (DAS28) was 4, indicating fairly high levels of functional impairment and disease activity, respectively. Researchers also found significant differences between depressed and non-depressed patients related to race, public versus university hospital, functional limitation and disease modifying anti-rheumatic drug (DMARD) treatment. Differences in depression severity were not impacted by gender, age, disease duration, steroid use and dose, or biologic therapy.

Furthermore, the team found that county hospital patients also had significantly higher depression scores (PHQ-9 of 7.3) than patients at the university medical center (PHQ-9 of 5.7). An interaction existed between socioeconomic status and disability such that the association of functional limitation with depression scores was stronger for patients at the public hospital clinic compared to those at the tertiary-care clinic.

Dr. Margaretten concluded, "For the same level of disability, patients with low SES may be more likely to experience depression. Detection and documentation of the differing effects of disability on depression between patients of different socioeconomic status can help rheumatologists improve health outcomes by initiating appropriate and timely treatment for depression."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Neighborhood socioeconomic status and diabetes
2. Socioeconomic status predicts survival of Canadian cancer patients
3. Sociologist finds combat veterans face more lifelong socioeconomic challenges
4. Insurance and socioeconomic status do not explain racial disparities in breast cancer care
5. AHIP Statement on the Status of Health Care Reform
6. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
7. AHIP Statement on the Status of Health Care Reform
8. Insurance status of gunshot trauma patients affects mortality outcomes
9. New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly
10. Teaching hospital status associated with death rate after colon surgery
11. Better vitamin D status could mean better quality of life for seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... ... The Journal of Pain Research has published the commentary “ Terminology of ... Dr John F. Peppin says “Terminology matters, yet little attention has been paid to ... cancer pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... The guide will ensure lab personnel have a basic understanding of the techniques ... measurement protocols. Enhanced understanding will help them reduce waste and rework to create ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... cleaning and sealing company , is proud to announce that many of their ... levels of customer service. The hard surface restoration franchises received customer recognition through ...
(Date:2/8/2016)... PLAINSBORO, N.J. (PRWEB) , ... February 08, 2016 , ... ... on cancer patients, has officially launched the Multiple Myeloma Heroes Awards event , ... (MM) or in the lives of patients with MM. The MM Heroes Awards ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... its fiscal 2016 first quarter ended December 31, 2015. ... Fiscal 2016 First Quarter Highlights , Revenue of ... quarter of 2015 , Domestic Radiation Measurement services revenues ...
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... Feb. 9, 2016 Mast Therapeutics, Inc. ... for sickle cell disease and heart failure, today announced that ... to purchase common stock in an underwritten public offering.  The ... can be no assurance as to whether or when the ... or terms of the offering.   --> ...
Breaking Medicine Technology: